Sirolimus-eluting stents have dramatically reduced the risk of instent restenosis following percutaneous coronary intervention. It is unclear whether the magnitude of this benefit is similar between patients with and without diabetes. We analyzed the results of the diabetes subanalysis of the SIRIUS trial to determine whether drug-eluting stents are safe and effective in patients with diabetes and determined that they are effective in reducing angiographic and clinical recurrence to a level similar to non-diabetic patients.
|Original language||English (US)|
|State||Published - Dec 1 2005|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine